The Trend in the Sales of Menopausal Hormone and Other Osteoporosis Medications in South Korea from 2016 to 2019
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Increasing geriatric population, osteoporosis prevalence, and interest in bone health are key contributing factors for the growth of osteoporosis medication markets. Thus, this study evaluated changes in the menopausal hormone and other osteoporosis medication markets from 2016 to 2019. Methods: This study’s dataset was obtained from the International Marketing Services of IQVIA Inc. in South Korea. The sales of medications for osteoporosis treatment with menopausal hormones were evaluated for drug sales for osteoporosis treatment from 2016 to 2019. Results: The results showed that the tissue-selective estrogen complex (TSEC) sales had increased annually while the estrogen-progesterone therapy (EPT) sales had decreased. Excluding menopausal hormones, bisphosphonates were the most widely sold medications for osteoporosis treatment. Among the bisphosphonate medications, sales of ibandronate and zoledronate increased annually, while alendronate and risedronate decreased. Teriparatide also showed increasing sales. A rapid rise was noted in the sales of denosumab. Conclusions: While the sales of TSEC, injectable bisphosphonates, and denosumab have increased annually, the sales of EPT, estrogen therapy, oral bisphosphonates have not increased, as reflected in hormone therapy and osteoporosis medication market trends. This study showed the recent trends in hormone therapy and the osteoporosis medication market from 2016 to 2019 in South Korea.
Abstract
Background: Increasing geriatric population, osteoporosis prevalence, and interest in bone health are key contributing factors for the growth of osteoporosis medication markets. Thus, this study evaluated changes in the menopausal hormone and other osteoporosis medication markets from 2016 to 2019. Methods: This study’s dataset was obtained from the International Marketing Services of IQVIA Inc. in South Korea. The sales of medications for osteoporosis treatment with menopausal hormones were evaluated for drug sales for osteoporosis treatment from 2016 to 2019. Results: The results showed that the tissue-selective estrogen complex (TSEC) sales had increased annually while the estrogen-progesterone therapy (EPT) sales had decreased. Excluding menopausal hormones, bisphosphonates were the most widely sold medications for osteoporosis treatment. Among the bisphosphonate medications, sales of ibandronate and zoledronate increased annually, while alendronate and risedronate decreased. Teriparatide also showed increasing sales. A rapid rise was noted in the sales of denosumab. Conclusions: While the sales of TSEC, injectable bisphosphonates, and denosumab have increased annually, the sales of EPT, estrogen therapy, oral bisphosphonates have not increased, as reflected in hormone therapy and osteoporosis medication market trends. This study showed the recent trends in hormone therapy and the osteoporosis medication market from 2016 to 2019 in South Korea.
참고문헌 (20)
- 하용찬, "한국 골다공증의 역학", 대한의사협회지, 59(11), pp.836~841 (2016), 대한의사협회[DOI]
- Hyung Jin Choi, "Burden of osteoporosis in adults in Korea: a national health insurance database study", Journal of Bone and Mineral Metabolism, 30(1), pp.54~58 (2012), Springer Science and Business Media LLC[DOI]
- Chan Soo Shin, "Prevalence and risk factors of osteoporosis in Korea: A community-based cohort study with lumbar spine and hip bone mineral density", Bone, 47(2), pp.378~387 (2010), Elsevier BV[DOI]
- Pamela S. Hinton, "Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: A 12-month randomized, clinical trial", Bone, 79, pp.203~212 (2015), Elsevier BV[DOI]
- Korean Society for Bone, "Physician’s guide for osteoporosis", Korean Society for Bone and Mineral Research, ~ (2020)
- Dennis M. Black, "Postmenopausal Osteoporosis", New England Journal of Medicine, 374(3), pp.254~262 (2016), Massachusetts Medical Society[DOI]
- 박형무, "한국의 골다공증 약제의 사용 현황", Obstetrics & Gynecology Science, 53(02), pp.152~159 (2010), 대한산부인과학회
- Park HM, "The use of osteoporosis medications in Korea in 2008", Korean J Bone Metab, 16, pp.87~93 (2009)
- Nam iLee, "The secular trends in the use of medications for osteoporosis in South Korea using Intercontinental Medical Statistics Health Sales Audit 2006–2018", Osteoporosis and Sarcopenia, 6(4), pp.185~190 (2020), 대한골다공증학회[DOI]
- Thomas J. Berrodin, "Differential Biochemical and Cellular Actions of Premarin Estrogens: Distinct Pharmacology of Bazedoxifene-Conjugated Estrogens Combination", Molecular Endocrinology, 23(1), pp.74~85 (2009), The Endocrine Society[DOI]
- James H. Pickar, "Tissue selective estrogen complex (TSEC): a review", Menopause, 25(9), pp.1033~1045 (2018), Ovid Technologies (Wolters Kluwer Health)[DOI]
- 이동윤, "Tissue-Selective Estrogen Complex and Breast", 대한폐경학회지, 26(2), pp.99~103 (2020), 대한폐경학회[DOI]
- 채희동, "Awareness and Experience of Menopausal Symptom and Hormone Therapy in Korean Postmenopausal Women", 대한폐경학회지, 20(1), pp.7~13 (2014), 대한폐경학회
- Y.-K. Lee, "Persistence with intravenous zoledronate in elderly patients with osteoporosis", Osteoporosis International, 23(9), pp.2329~2333 (2012), Springer Science and Business Media LLC[DOI]
- Joyce A. Cramer, "Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis", Current Medical Research and Opinion, 21(9), pp.1453~1460 (2005), Informa Healthcare[DOI]
- A. COOPER, "Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study", International Journal of Clinical Practice, 60(8), pp.896~905 (2006), Hindawi Limited[DOI]
- 이유진, "Which Bisphosphonate? It’s the Compliance!: Decision Analysis", 대한골대사학회지, 23(2), pp.79~83 (2016), 대한골대사학회[DOI]
- Emma D. Deeks, "Denosumab: A Review in Postmenopausal Osteoporosis", Drugs & Aging, 35(2), pp.163~173 (2018), Springer Science and Business Media LLC[DOI]
- P. Hadji, "GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab", Osteoporosis International, 27(10), pp.2967~2978 (2016), Springer Science and Business Media LLC[DOI]
- Korean Society for Bone, "Physician’s guide for osteoporosis", Korean Society for Bone and Mineral Research, ~ (2018)